Introduction: Gastric cancer (GC) is one of the leading causes of cancer-related mortality worldwide, with two predominant histological subtypes: the intestinal type, often associated with Helicobacter pylori infection, and the diffuse type, characterized by poorly cohesive cells, whose risk factors are endogenous (genetic) and exogenous (environmental). Given its etiological complexity and heterogeneous distribution across populations, numerous observational studies have investigated gastric cancer patterns. However, methodological variability among these studies may compromise result comparability and evidence consistency, underscoring the importance of the STROBE guidelines (Strengthening the Reporting of Observational Studies in Epidemiology), which provide a standardized checklist to enhance transparency, quality, and reproducibility in observational research. Assessing their application is crucial to strengthen available evidence and guide more effective clinical practices and public health policies. Objectives: To evaluate the compliance of cross-sectional studies on gastric cancer from PubMed with the STROBE guidelines. Methods: This is an analytical cross-sectional study based on articles retrieved from PubMed using the following search descriptors: ("Stomach Neoplasms"[Mesh]) AND ("Cross-Sectional Studies"[Mesh]). Inclusion criteria: Original observational cross-sectional studies addressing clinical, epidemiological, or quality-of-life aspects of gastric cancer. Exclusion criteria: Reviews, letters, editorials, experimental studies, and studies with incomplete data. Screening and selection were performed by two independent reviewers in successive stages (title, abstract, and full-text reading). Methodological quality was assessed using the STROBE checklist, with studies meeting ?80% of the items classified as satisfactory. Results: The search analyzed 197 articles, with 127 studies (2014–2025) included in the final analysis. Most publications were from Asia (China, South Korea, Japan), with relevant contributions from Brazil, the United States, and Europe. The studies examined epidemiological patterns of gastric cancer and gastrointestinal diseases across populations, highlighting key risk factors such as H. pylori, family history, diagnostic strategies, and clinical management. The most frequent study design was cross-sectional (92.1%), followed by cohort studies, systematic reviews, economic analyses, and observational clinical trials. While most studies adequately described objectives and methodology, heterogeneity was observed in reporting inclusion/exclusion criteria. Regarding STROBE compliance, only a minority of studies met >80% of the checklist items. The prevalence of gastric cancer ranged from 2.4% to 10%, while H. pylori infection rates varied between 11.3% and 87%, particularly in high-risk populations. Although statistical analyses were robust in some studies, common limitations included selection bias and small sample sizes. Conclusion: While scientific output on gastric cancer has grown in recent years—especially in Asian countries—methodological heterogeneity remains a concern. The predominance of cross-sectional designs and low adherence to STROBE criteria reveal weaknesses in reporting quality, affecting result comparability and applicability. Although risk factors like H. pylori and family history are consistently associated with gastric cancer, recurrent methodological limitations (selection bias, small samples) highlight the need for better-structured observational studies with greater transparency, standardization, and rigor in execution and reporting. Thus, systematic use of guidelines like STROBE is essential to improve evidence quality and support more effective clinical and public health policies.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
